Advancements in Patient-Centered Care

Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.

Carter, Barragán, Miller-Meeks successfully push Biden administration to protect patients’ access to life-saving medications

January 19, 2024

WASHINGTON, D.C. – Reps. Earl L. “Buddy” Carter (R-GA), Nanette Barragán (D-CA), and Mariannette Miller-Meeks (R-IA) today celebrated the Biden administration’s decision to drop its appeal in a case against the patient community, keeping in effect the District of Columbia’s District Court ruling affirming the 2020 Notice of Benefit and Payment Parameters (NBPP) Final Rule requiring that […]
read more

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

December 6, 2023

– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quality of life – STAMFORD, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on […]
read more

World Leaders in Medically Integrated Oncology Set to Gather at NCODA’s 2023 Summit to Further Elevate Patient Care

October 23, 2023

– Integrated cancer care professionals to address treatments, shortages, and operational advances driving improved outcomes –   Orlando, FL – October 23, 2023 – Physicians, nurses, pharmacists, and other important clinical and administrative team members, along with partnering pharmaceutical industry representatives from all over the world will gather in Orlando October 25-27 for the NCODA […]
read more

Effective October 1, 2023, ICD-10-CM Diagnosis Codes Are Available for Desmoid Tumors

October 16, 2023

Desmoid tumors are rare, locally aggressive soft tissue tumors1 Until October 1, 2023, desmoid tumors fell under an ICD-10-CM code (D48.1) covering a variety of connective and soft tissue tumors of “uncertain behavior”2 As of October 1, 2023, ICD-10-CM diagnosis codes are available for desmoid tumors2   On October 1, 2023, location-specific International Classification of […]
read more

PAN announces opposition to alternative funding programs

June 14, 2023

JUNE 13, 2023 The PAN Foundation today announced opposition to alternative funding programs, which jeopardize patient access to specialty medications and redirect finite charitable funds away from uninsured and underinsured patients. We urge Congress and the administration to learn about the growing use of alternative funding programs, understand their detrimental impact on patients, and evaluate options […]
read more

FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

May 25, 2023

May 22, 2023 at 4:04 PM EDT — For the first time, patients with indolent SM have a medicine that treats the primary disease driver and is proven to provide broad and durable symptom relief — — Approval based on the positive PIONEER trial, in which once-daily AYVAKIT achieved significant improvements in disease symptoms and […]
read more

CMS Guidance on Practices Delivering Medications Violating the Stark Law

April 27, 2023

[CAZENOVIA, NY – April 27, 2023] – NCODA urges the Centers for Medicare & Medicaid Services (CMS) to immediately retract a portion of a Frequently Asked Questions (FAQ) that suggests that physician practices mailing medications would violate the federal prohibition on self-referral for ancillary services (Stark law). At present, the Public Health Emergency (PHE) that […]
read more

New Oncology Pharmacy Course to Fulfill Vital Training Need for Future Professionals

March 30, 2023

[CAZENOVIA, NY – March 30, 2023] – NCODA University, a division of NCODA that provides top-tier education for future and present oncology pharmacists, has launched a new 15-hour Oncology Basics Course. This first-of-its-kind course will reinforce knowledge of the etiology and pathophysiology of cancer, provide a deeper understanding of commonly used anti-cancer drug classes, and […]
read more

U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

March 10, 2023

— First Trop-2 Directed ADC to Demonstrate Overall Survival Benefit in HR+/HER2- Metastatic Breast Cancer Patients who had Received Prior Endocrine-based Therapy and at Least Two Chemotherapies — — Trodelvy has Now Improved Survival in both Pre-Treated HR+/HER2- Metastatic Breast Cancer and in Second-Line Metastatic Triple-Negative Breast Cancer —   FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. […]
read more


Cost Avoidance Waste Tracker

Positive Quality Interventions

PQI in Action

OCE Sheets

IVE Sheets

Treatment Support Kits

PQI Podcast


Member Resources



Member Login



Spring Forum

Oncology Institute

PSO Annual Meeting

Fall Summit


P.O. Box 468
Cazenovia, NY 13035

NCODA is a 501(c)(3) Organization